Systems and methods for targeted imaging and ablation of cardiac cells
The present invention relates to nanoparticles. In particular, the present invention provides nanoparticles for clinical (e.g., targeted therapeutic), diagnostic (e.g., imaging), and research applications in the field of cardiology. For example, in some embodiments, the present invention provides a method of treating (e.g., ablating) cardiac tissue, comprising: a) contacting an animal with a nanoparticle comprising a matrix, a toxic (e.g., ablative) agent (e.g., sonosensitizer, chemotherapeutic agent (e.g., doxorubicin or cisplatin), or photosensitizer), and a cardiac targeting moiety; and b) administering an activator of the toxic agent (e.g., light, chemical (e.g., pharmaceutical agent) or ultrasound) to at least a portion of the cardiac tissue (e.g., heart) of the animal to activate the toxic agent.
1. A method of ablating cardiomyocytes, comprising:
a) contacting an animal with a nanoparticle comprising a polymeric or glass matrix, a photosensitizer, and a cardiac targeting peptide, wherein said cardiac targeting peptide has the amino acid sequence of SEQ ID NO:1; wherein said cardiac targeting peptide is specific to cardiomyocytes; and
b) administering light to activate said photosensitizer to at least a portion of the cardiomyocytes of said animal, wherein said administering results in ablation of the cardiomyocytes where said light is administered.
2. The method of claim 1 , wherein said light is emitted from a laser.
3. The method of claim 1 , wherein said photosensitizer is selected from the group consisting of methylene blue, chlorin e6 (Ce6), porfimer sodium, 2-devinyl-2-(1-hexyloxyethyl) pyropheophorbide (HPPH), coomasie blue and gold.
4. The method of claim 1 , wherein said contacting is via intravenous administration.
5. The method of claim 1 , wherein said animal is a human.
6. The method of claim 1 , wherein said animal exhibits atrial fibrillation and said ablation reduces said atrial fibrillation relative to the level of atrial fibrillation prior to said ablation.
7. The method of claim 1 , further comprising the step of imaging said nanoparticle in said animal.
8. The method of claim 7 , further comprising the step of determining a treatment course of action based on said imaging, wherein said treatment course of action comprises repeating the step of administering said activator and/or nanoparticles when said imaging identifies cardiac tissue in need of ablating.
9. The method of claim 1 , wherein said nanoparticle is approximately 10 nm or less in size.
10. The method of claim 1 , wherein said polymeric or glass matrix is selected from the group consisting of polyacrylamide, polyvinylchloride, decy-methacrylate, and a sol-gel, and polyethylene glycol (PEG).